Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes & Liquid Biopsies Europe 2018

Douglas Horejsh's Biography

Douglas Horejsh, Senior Research Scientist, Promega Corporation

Dr. Douglas Horejsh is a Senior Research Scientist in the Protein and Nucleic Acid Analysis Division of Research & Development at Promega Corporation. He is interested in development of nucleic acid purification systems to yield high quality nucleic acids from challenging starting samples. His group develops purification chemistries in manual, Maxwell® and large instrument formats, along with fluorescent dyes for nucleic acid detection.

Prior to joining Promega, Douglas was a clinical lab director for a molecular pathology company in Virginia. His work focused on identification, evaluation, validation, and integration of IVD and LDT assays in a clinical lab setting. He also managed BSL-3 facilities and led research on emerging/biodefense pathogens. Prior to moving to the East Coast, Douglas worked for 4 years in the Virology Department of the Italian National Institute for Infectious Diseases in assay development.

Douglas has authored 20 journal articles and is an inventor of issued world and Italian patents. He received his Ph.D. in 2001 from the University of Wisconsin-Madison and trained as a post-doc at the Institute of Human Virology in Baltimore, MD.

Douglas  Horejsh Image

Efficient, Automated Purification of ccfDNA From Plasma

Wednesday, 24 October 2018 at 16:00

Add to Calendar ▼2018-10-24 16:00:002018-10-24 17:00:00Europe/LondonEfficient, Automated Purification of ccfDNA From PlasmaExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The

While circulating cell-free DNA (ccfDNA) is one of the most promising sources of DNA-based information for oncology research available today, scientists continue to look for better ways to actively target the precious small fragment DNA necessary for liquid biopsy applications.

The use of ccfDNA as a sample type is not without its challenges. The low concentration and highly fragmented nature of ccfDNA, coupled with the low frequency of biomarkers of interest, present many challenges to the adoption of ccfDNA monitoring. Variations inherent to the sample type, as well as sample handling, can affect the amount of contaminating high molecular weight gDNA. Presence of high levels of contaminating gDNA may result in difficulty detecting low-level mutations present in the minor component ccfDNA

We have developed novel nucleic acid purification chemistries that improve upon current manual and automated methods for the purification of DNA from plasma and demonstrate their use in downstream assays. In addition, we seek to provide tools to assess DNA quantity to understand the composition of the nucleic acid obtained.  In those cases where samples have been contaminated by gDNA, we have created applications where we can enrich for the ccfDNA component of a sample, thereby eliminating larger material and effectively decreasing background without affecting levels of the 170bp fragment.

Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The